Blood Cancer Talks

In this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed: 

1.      STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCL
2.     Epco-Pola-R-CHP for 1st line DLBCL (EPCORE NHL-5 study):
3.     3-year follow-up of TRANSFORM (Liso-Cel vs CITàASCT in R/R DLBCL):
4.     ECHO RCT: Acalabrutinib-BR vs Placebo-BR in previously untreated elderly MCL:
5.     HD21: escBEACOPP vs BrECADD in 1st line classical HL:
6.     Combination pirtobrutinib, venetoclax, and obinutuzumab in 1st line CLL:
7.      Single-agent epcoritamab in Richter’s transformation: EPCORE CLL-1:

What is Blood Cancer Talks?

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk